M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘ KGaA, Darmstadt, Germany's core business areas. From our headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. M Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck KGaA, Darmstadt, Germany's science and technology base.
Location: Netherlands, North Holland, Amsterdam
Employees: 11-50
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 77
| Date | Name | Website | Total Raised | Location |
| 21.05.2024 | LabGenius | labgeni.us | $79.69M | United Kin... |
| 16.07.2023 | DNA SCRIPT | dnascript.co | $311.17M | - |
| 16.07.2023 | Astraveus | astraveus.com | $29.1M | - |
| 14.04.2023 | ImmuneBrid... | immunebridge.com | $12M | United Sta... |
| 12.03.2023 | Iktos | iktos.ai | $16.62M | France, Il... |
| 21.02.2023 | Calypso Bi... | calypsobiotech.com | $55.8M | Netherland... |
| 18.02.2023 | Unisers | unisers.ch | $14M | Switzerlan... |
| 08.11.2022 | Concerto B... | concertobio.com | $47.54M | United Sta... |
| 08.11.2022 | Micropsi I... | micropsi-industries.com | $36.08M | Germany, B... |
| 08.11.2022 | Immunitas ... | immunitastx.com | $97M | United Sta... |
Show more
News 51
| Date | Title | Description |
| 29.01.2022 | Future Fertility Raises Series A to Progress First-In-Class AI-Enabled Fertility Solutions to Improve IVF Outcomes | First company to develop an AI product to predict egg viability with potential to significantly improve IVF outcomes Financing led by M Ventures with participation from Whitecap Venture Partners |
| 11.12.2021 | DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing Platform | New Funding, Targeted to Accelerate Application Expansion and Platform Commercialization, Brings Total Amount Raised to Date to $280M |
| 11.12.2021 | Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian University | Research collaboration will identify new opportunities in the fight against Alzheimer’s and further validate the predictive diagnostic capabilities of Altoida’s software medical device. |
| 11.12.2021 | NanoSyrinx announces oversubscribed £6.2M Seed+ funding round to develop its novel biologic delivery platform | NanoSyrinx has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck KGaA. Previous investors BioCity and the ... |
| 11.12.2021 | Merck KGaA, Darmstadt, Germany, Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million | Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures |
| 11.12.2021 | iOmx Therapeutics raises EUR 65 million in Series B round | Martinsried / Munich, Germany, 5 October, 2021: iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the closing of a Series B round tot... |
| 11.12.2021 | AI Chip Innovator MemryX Hires Veteran Semiconductor Leader Keith Kressin as CEO | Keith Kressin appointed as new president and CEO |
| 11.12.2021 | Altoida Awarded FDA Breakthrough Designation for Development of World’s First Precision Neurology Device for Prediction of Alzheimer's Disease | Breakthrough Designation will advance the development of industry’s first predictive diagnostic device for conversion to Alzheimer’s disease, backed by two decades of global clinical studies |
| 11.12.2021 | DNA Script Obtains CE Mark for SYNTAX DNA Printing Platform | DNA Script, a leader in Enzymatic DNA Synthesis (EDS), announced the CE marking of its SYNTAX System, the first EDS-powered benchtop DNA printer |
| 22.11.2021 | Xilio Therapeutics Announces Closing of Initial Public Offering | Xilio Therapeutics, Inc. today announced the closing of its previously announced initial public offering of 7,353,000 shares of its common stock at a price to the public of $16.00 per share |
Show more
Mentions in press and media 50
| Date | Title | Description |
| 18.07.2024 | Asceneuron's $100M Series C Funding Boosts Alzheimer's Disease Research | Asceneuron, a Lausanne-based clinical-stage biotech company, has recently announced the successful completion of a $100 million Series C financing round. This significant funding boost, led by Novo Holdings and supported by EQT Life Science... |
| 16.07.2024 | Asceneuron closes $100 million series C financing round | Asceneuron SA, a Lausanne-based clinical-stage biotech company developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease, announces its $100 million oversubscribed Series C financing round. The... |
| 16.07.2024 | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round Tue, Jul 16, 2024 09:15 CET Report this content EQT Life Sciences has invested in Asceneuron’s oversubscr... |
| 25.06.2024 | iOnctura's Precision Cancer Treatments Gain Momentum | iOnctura, a clinical-stage biopharmaceutical company based in Amsterdam, recently secured EUR80 million in Series B financing to accelerate the development of their lead asset, roginolisib, for the treatment of uveal melanoma and other onco... |
| 24.06.2024 | iOnctura closes EUR80 million Series B financing | iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces that it has closed an EUR80 million Series B financing. The funding round was led by new investor Syncona Limited with part... |
| 21.05.2024 | UK’s LabGenius secures €40.9M led by Amsterdam’s M Ventures to advance its drug discovery platform | Read this article in: London-based LabGenius, a drug discovery company, announced that it has secured £35M (approximately €40.96M) in a Series B round of funding. The company specialises in using machine learning to discover new therapeutic... |
| 17.04.2024 | Mosa Meat Secures €40M to Revolutionize Cultivated Beef Market | Mosa Meat, a Dutch cultivated meat company, has secured a whopping €40 million in funding to accelerate its mission of transforming the beef industry. The investment will drive production scale-up, cost reduction, and market entry preparati... |
| 16.04.2024 | Mosa Meat Secures €40M in Funding to Expand Production and Speed Up Launch of Cultivated Meat | 5 Mins Read Dutch cultivated meat pioneer Mosa Meat has raised €40M ($42.4M) in a new funding round to support the “next phase” of the company’s growth, with a public tasting of its burger imminent ahead of its launch in Singapore. The comp... |
| 16.04.2024 | Maastricht-based Mosa Meat raises €40 million to help bring cultivated beef to consumers | - |
| 05.04.2024 | Nucleai Revolutionizes Clinical Trials with $14M Funding Boost | Nucleai, a pioneer in spatial AI biomarkers, has secured a hefty $14M in funding led by M Ventures, the corporate venture arm of Merck KGaA. This investment brings Nucleai's total funding to a solid $60M, fueling their mission to transform ... |
Show more